These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 26676219)

  • 1. Muscarinic Receptor Binding and Plasma Drug Concentration after the Oral Administration of Propiverine in Mice.
    Ito Y; Kato A; Fujino Oki T; Okura T; Yoshida K; Nanri M; Yamada S
    Low Urin Tract Symptoms; 2010 Apr; 2(1):43-9. PubMed ID: 26676219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
    Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
    Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
    Oki T; Sato S; Miyata K; Yamada S
    Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
    Uchida S; Kurosawa S; Fujino Oki T; Kato Y; Nanri M; Yoshida K; Yamada S
    Life Sci; 2007 Jun; 80(26):2454-60. PubMed ID: 17512953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
    Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
    Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine.
    Oki T; Yamada S; Tohma A; Kimura R
    Biol Pharm Bull; 2001 May; 24(5):491-5. PubMed ID: 11379767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
    Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
    J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
    Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
    J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
    Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
    Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard.
    Yoshida A; Seki M; Nasrin S; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Ehlert FJ; Yamada S
    Urology; 2011 Sep; 78(3):721.e7-721.e12. PubMed ID: 21777958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of muscarinic and nicotinic receptor binding activities of distigmine to treat detrusor underactivity.
    Harada T; Fushimi K; Kato A; Ito Y; Nishijima S; Sugaya K; Yamada S
    Biol Pharm Bull; 2010; 33(4):653-8. PubMed ID: 20410601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of muscarinic receptor binding by the novel radioligand, [(3)H]imidafenacin, in the bladder and other tissues of rats.
    Kuraoka S; Ito Y; Wakuda H; Shinozuka K; Onoue S; Yamada S
    J Pharmacol Sci; 2016 Jul; 131(3):184-9. PubMed ID: 27430986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
    J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland.
    Seki M; Ogoda M; Kuraoka S; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
    Low Urin Tract Symptoms; 2011 Sep; 3(2):64-8. PubMed ID: 26676388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
    Oki T; Kawashima A; Uchida M; Yamada S
    Life Sci; 2005 Apr; 76(21):2445-56. PubMed ID: 15763076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
    Yoshida A; Fuchihata Y; Kuraoka S; Osano A; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
    Urology; 2013 Apr; 81(4):920.e1-5. PubMed ID: 23497983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of nicotinic and muscarinic receptor mRNA in rat bladder by repeated administration of nicotine in relation to the pharmacokinetics.
    Yamamoto N; Yoshida A; Taki Y; Onoue S; Kagawa Y; Yamada S
    Life Sci; 2011 Aug; 89(9-10):343-8. PubMed ID: 21762705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.
    Yamada S; Kuraoka S; Osano A; Ito Y
    Int Neurourol J; 2012 Sep; 16(3):107-15. PubMed ID: 23094215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.